Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 10/20 | 0.73 |
| ▸ | ADRB2 | P07550 | 9/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3600021 | 0.95 | SMYD2 (0.69) | SMYD2ADRB2ADRB1DRD2DRD1 | |
| SCHEMBL3600605 | 0.93 | SMYD2 (0.73) | SMYD2ADRB2ADRB1DRD2DRD1 | |
| SCHEMBL3603639 | 0.93 | SMYD2 (0.84) | SMYD2ADRB2ADRB1DRD2DRD1 | |
| SCHEMBL3597803 | 0.93 | SMYD2 (0.84) | SMYD2ADRB2ADRB1DRD2DRD1 | |
| SCHEMBL3590085 | 0.92 | SMYD2 (0.84) | SMYD2ADRB2ADRB1DRD2DRD1 | |
| SCHEMBL3606169 | 0.92 | SMYD2 (0.85) | SMYD2ADRB2ADRB1DRD2DRD1 | |
| SCHEMBL3598223 | 0.92 | SMYD2 (0.85) | SMYD2ADRB2ADRB1DRD2DRD1 | |
| SCHEMBL3597329 | 0.92 | SMYD2 (0.71) | SMYD2ADRB2ADRB1DRD2DRD1 | |
| SCHEMBL3606054 | 0.91 | SMYD2 (0.70) | SMYD2ADRB2ADRB1DRD2DRD1 | |
| SCHEMBL3603197 | 0.89 | SMYD2 (0.72) | SMYD2ADRB2ADRB1DRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142646-A1 | Novel Compounds 621 | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | claimed |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | claimed |
| EP-2094646-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | AstraZeneca AB (SE) | 2009-09-02 | — | — | EP | claimed |
| WO-2008075025-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | claimed |
| US-20120142646-A1 | Novel Compounds 621 | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142646-A1 | Novel Compounds 621 | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | disclosed |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | disclosed |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | disclosed |
| WO-2008075025-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142646-A1 | Novel Compounds 621 | AR, ADRA1D, ADRA1B | SMYD2 3203/4885ADRB2 18/4885ADRB1 4/4885 |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ADRB2, ADRB1, ADRA2A | SMYD2 1024/4885ADRB2 1/4885ADRB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.